|
|
Table 3. Clinical Trials of Psychostimulants in Cancer Patients
Study
|
Comments
|
Drug(s)
|
Outcome
|
Meyers et al. 1998 [37] |
Brain tumor; N = 30 |
methylphenidate (Ritalin) |
↑ mood, ↑ cognition, ↑ function |
Olin and Masand 1996 [38] |
Mixed cancer; N = 59; chart review |
dextroamphetamine (Dexedrine); methylphenidate (Ritalin) |
↓ depression, ↑ appetite |
Bruera et al. 1992 [39] |
Cancer pain vs. opioid infusion; N = 20 |
methylphenidate (Ritalin); placebo |
↑ cognition, ↓ sedation |
Fernandez et al. 1987 [36] |
Mixed cancer; rapid onset; N = 30 |
methylphenidate (Ritalin;up to 80 mg) |
↓ depression |
Bruera et al. 1986 [40] |
Pain; double-blind cross-over study; N = 24 |
mazindol (Mazanor) |
↓ pain, ↓ appetite, no effect on mood
|
Joshi et al. 1982 [41] |
Terminally ill |
amphetamine |
↑ comfort |
References
-
Fernandez F, Adams F, Holmes VF, et al.: Methylphenidate for depressive disorders in cancer patients. An alternative to standard antidepressants. Psychosomatics 28 (9): 455-61, 1987.
[PUBMED Abstract]
-
Meyers CA, Weitzner MA, Valentine AD, et al.: Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 16 (7): 2522-7, 1998.
[PUBMED Abstract]
-
Olin J, Masand P: Psychostimulants for depression in hospitalized cancer patients. Psychosomatics 37 (1): 57-62, 1996 Jan-Feb.
[PUBMED Abstract]
-
Bruera E, Miller MJ, Macmillan K, et al.: Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain 48 (2): 163-6, 1992.
[PUBMED Abstract]
-
Bruera E, Carraro S, Roca E, et al.: Double-blind evaluation of the effects of mazindol on pain, depression, anxiety, appetite, and activity in terminal cancer patients. Cancer Treat Rep 70 (2): 295-8, 1986.
[PUBMED Abstract]
-
Joshi JH, de Jongh CA, Schnaper N, et al.: Amphetamine therapy for enhancing the comfort of terminally ill patients with cancer. Proceedings of the American Society of Clinical Oncology 1: 55, 1982.
|
|
|